Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Phase II Trial
100%
Chronic Myeloid Leukemia
100%
Complete Remission
100%
Single Center
100%
Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia
100%
Decitabine
100%
Ponatinib
100%
Venetoclax
100%
Advanced Phase
100%
Tyrosine Kinase Inhibitor
62%
BCR-ABL1 Tyrosine Kinase
62%
Hematological Recovery
50%
Philadelphia Chromosome
37%
Accelerated Phase
37%
Chemotherapy
25%
Intention-to-treat
25%
Chronic Myeloid Leukemia Blast Phase
25%
High Risk
12%
Leukemia
12%
Oncology
12%
Combination Therapy
12%
Poor Outcome
12%
Clinical Data
12%
Previously Untreated
12%
Hispanic
12%
National Institutes of Health
12%
Cardiovascular Events
12%
Maximum Tolerated Dose
12%
National Cancer Institute
12%
Eastern Cooperative Oncology Group Performance Status (ECOG PS)
12%
Phase I Study
12%
Febrile Neutropenia
12%
Aspartate Transaminase
12%
Free State
12%
Response-adapted
12%
Third Generation
12%
Recovery Rate
12%
Novel Combinations
12%
High-risk Disease
12%
Myeloid Disorders
12%
Transaminase Elevations
12%
Complex Karyotype
12%
Inhibitor Combination
12%
BCR-ABL Transcript
12%
Additional Chromosomal Abnormalities
12%
Acute Myeloid
12%
Combination Strategy
12%
Blast Phase
12%
Rare Group
12%
Disease Features
12%
Relapsed/refractory
12%
BCL-2 Inhibitor
12%
Hematological Adverse Events
12%
Optimal Regimen
12%
Alanine Transaminase
12%
Clinical Infection
12%
Refractory Leukemia
12%
Myeloid Blast
12%
Composite Rate
12%
Non-haematological
12%
Line of Therapy
12%
Medicine and Dentistry
Arm
100%
Acute Myeloid Leukemia
100%
Myeloid Leukemia
100%
Decitabine
100%
Philadelphia 1 Chromosome
100%
Venetoclax
100%
Ponatinib
100%
Chronic Myelogenous Leukemia
62%
Tyrosine-Kinase Inhibitor
62%
Diseases
37%
Malignant Neoplasm
25%
Infection
25%
Intention-to-Treat Analysis
25%
Oncology
25%
Leukemia
25%
Chemotherapy
25%
Prospective Study
12%
Combination Therapy
12%
Adverse Event
12%
Morphology
12%
Karyotype
12%
Alanine Aminotransferase
12%
Aspartate Aminotransferase
12%
Febrile Neutropenia
12%
Chromosome Aberration
12%
Chronic Myelogenous Leukemia
12%
Cardiovascular System
12%
Pharmacology, Toxicology and Pharmaceutical Science
Remission
100%
Acute Myeloid Leukemia
100%
Decitabine
100%
Philadelphia 1 Chromosome
100%
Myeloid Leukemia
100%
Ponatinib
100%
Venetoclax
100%
Chronic Myeloid Leukemia
62%
Protein Tyrosine Kinase Inhibitor
62%
Diseases
37%
Malignant Neoplasm
25%
Infection
25%
Leukemia
25%
Chemotherapy Regimens
25%
Adverse Event
12%
Combination Therapy
12%
Aspartate Aminotransferase
12%
Prospective Study
12%
Febrile Neutropenia
12%
Alanine Aminotransferase
12%
Chromosome Aberration
12%